Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma.
H. Oettle
No relevant relationships to disclose
A. Hilbig
Other Remuneration - Antisense Pharma
T. Seufferlein
No relevant relationships to disclose
A. Tsianakas
No relevant relationships to disclose
T. Luger
No relevant relationships to disclose
R. M. Schmid
No relevant relationships to disclose
G. von Wichert
No relevant relationships to disclose
E. Endlicher
No relevant relationships to disclose
C. Garbe
No relevant relationships to disclose
K. K. Kaehler
No relevant relationships to disclose
A. Hauschild
No relevant relationships to disclose
A. Enk
No relevant relationships to disclose
P. Kiessling
Employment or Leadership Position - Antisense Pharma
S. Schmaus
Employment or Leadership Position - Antisense Pharma
H. Heinrichs
Employment or Leadership Position - Antisense Pharma
Stock Ownership - Antisense Pharma
K. Schlingensiepen
Employment or Leadership Position - Antisense Pharma
Stock Ownership - Antisense Pharma